tbuckley/cabot-search huggingface dataset:
Myelofibrosis and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RISCT).
Authors: Uday R. Popat, Gabriela Rondon, Amin M. Alousi, Paolo Anderlini, Borje S. Andersson, Marcos J. de Lima, Sergio A. Giralt, Chitra M. Hosing, Partow Kebriaei, Roy Jones, Yago Nieto, Elizabeth J. Shpall, Srdan Verstovesek, Muzaffar H. Qazilbash, Richard Champlin
Journal: Blood (2007)
Co-Expression of the UPRT Gene with the Human Nerve Growth Factor Receptor and Cytosine Deaminase Fusion Gene Using a Single Retroviral Vector Augments Cytotoxicity of Transduced Human T-Cells Exposed to 5-Fluorocytosine.
Authors: Tracey A. O’Brien, Dong T. Tuong, Lisa M. Basso, Paul J. Orchard
Journal: Blood (2004)
Multicenter Study of “off-the-Shelf” Third Party Virus-Specific T Cells (VSTs) to Treat Adenovirus (Adv), Cytomegalovirus (CMV) or Epstein Barr Virus (EBV) Infection After Hemopoietic Stem Cell Transplantation (HSCT)
Authors: Ann M. Leen, Catherine M. Bollard, Adam M. Mendizabal, Elizabeth J. Shpall, Paul Szabolcs, Joseph H. Antin, Neena Kapoor, Sung-Yun Pai, Scott D. Rowley, Partow Kebriaei, Bambi J. Grilley, Adrian P. Gee, Malcolm K. Brenner, Cliona M. Rooney, Helen E. Heslop
Journal: Blood (2012)
MPTH-32. MUTATION CHARACTERISTICS IN HIGH-GRADE GLIOMAS
Authors: Vassiliki Kotoula, Evangelia Razis, Eleni Giannoulatou, Eleni Vrettou, Elpida Charalambous, George Kouvatseas, Ioannis Tikas, Sotiris Papadopoulos, Styliani Papaemmanoyil, George Rigakos, Thomas Zaramboukas, Ourania Romanidou, Georgios Iliadis, Panagiotis Nomikos, Panagiotis Selviaridis, Konstantinos Polyzoidis, George Fountzilas
Journal: Neuro-Oncology (2016)

Despite the recent WHO molecular classification of gliomas, efforts to subclassify these tumors on the basis of their genetic/molecular features are still ongoing. Herein, we analyzed 121 paraffin DNA samples with informative parallel sequencing data from 107 patients (83 grade IV, 20 grade III, 9 grade II and 9 morphologically normal brain samples from different blocks); matched samples from the same resection were available in 9 cases. Patients with high-grade gliomas (n=99) had received standard chemoradiation. Mutations (amino acid changing variants with minor allele frequency <0.1%) were analyzed for incidence and possible clonality (variant allele frequency >25%). We identified 207 mutations (56 clonal; 27%) in 37 genes distributed in tumors from 63/107 patients (59%). TP53, EGFR, IDH1/2, NF1 and ATRX were the most frequently mutated genes. Clonal mutations were observed for TP53 in grade II-IV tumors (26/36; 72%); EGFR in grade III and IV (12/32; 37.5%); NF1 in grade IV only (3/14; 21%); IDH1/2 in grade II-IV, (16/16; 100%). TP53, EGFR, NF1 and ATRX mutations were found in 5/9 normal samples; only EGFR mutations were clonal. No IDH1/2 and NF1 co-mutated tumors were observed. Grade III and IV tumors were classified as IDH1/2 mutant, NF1 mutant, and IDH&NF1 wild-type. Upon multivariable analysis, the combined IDH/NF1 variable was an independent significant predictor of overall survival (Wald’s p=0.002); in comparison to patients with IDH&NF1 wild-type tumors, those with IDH1/2 mutations fared better, as expected (HR 0.3; 95%CI 0.11-0.73), while those with NF1 mutations fared worse (HR 2.4; 95%CI 1.07-5.28). In conclusion, within IDH-negative gliomas, NF1 mutations may distinguish a group of patients with worst outcome, probably reflecting the mesenchymal phenotype previously associated with such mutations. Despite that TP53 and EGFR mutations appear to occur early during glioma development and may occasionally be clonal, such mutations do not seem to affect patient outcome.
The use of next generation sequencing (NGS) to guide patient selection for phase 1 clinical trials
Authors: R.E. Miller, N.F. Brown, A. Speirs, H.M. Shaw, S. Adeleke, P. Gougis, P. Bennett, T. Meyer, C. Swanton, M. Forster, R.S. Kristeleit
Journal: Annals of Oncology (2016)
Increased Hepcidin Expression in Mice Affected by β-Thalassemia Reduces Iron Overload with No Effect on Anemia
Authors: Sara Gardenghi, Maria Franca Marongiu, Kristen Muirhead, Pedro Ramos, Cindy N. Roy, Nancy C. Andrews, Elizabeta Nemeth, Antonia Follenzi, Eliezer Rachmilewitz, Patricia Giardina, Robert W Grady, Stefano Rivella
Journal: Blood (2008)
MNGO-15. ANALYSIS OF GROWTH RATE OF MENINGIOMAS SELECTED FOR OBSERVATION WITHOUT TREATMENT
Authors: Charles Opalak, Adam Sima, Serendipity Rinonos, Vyshak Chandra, Kathryn Workman, Emmy Miller, Aravind Somasundaram, Sharon Wolber, William Broaddus
Journal: Neuro-Oncology (2016)

When meningiomas are asymptomatic, the decision to observe rather than treat requires balancing the growth potential of the lesion, patient age and expected longevity with the potential consequences and side effects of treatment. We set out to characterize the growth patterns of presumed meningiomas in our patient population to better inform this process. Patients with presumed meningiomas were identified from brain tumor related diagnoses between 2005 and 2015. Those without treatment who had been followed for 2 or more years with 3 or more MRI scans were included. Scans were measured with orthogonal diameters, geometric mean diameters (GMDs) and volumes using the ABC/2 method (simplified ellipsoid volume). Two hundred and ten scans for 34 female (85%) and 6 male (15%) patients with a total of 42 tumors were evaluated. Tumor volume ranged from 0.11cc to 14.5cc: the mean and median volumes were 3.18cc and 1.95cc respectively. Follow-up times ranged from 1.7 to 12 years. Regression analysis of the diameters and volumes identified 14 tumors (33%) whose tumor growth rates were significantly different from zero. The growth rates had slopes ranging from 0.11 to 1.95 mm/year for the maximum diameter, 0.09 to 1.78 mm/year for GMD and 0.03 to 2.03 cc/year for volume. A model that allowed for a normally distributed linear model (NNL) had the smallest prediction error for all three parameters (volume, largest diameter and GMD). Analysis of sequential scans for the population of patients undergoing monitoring without treatment demonstrates that approximately two thirds of tumors managed conservatively have zero growth and the remainders have tumor growth that can be approximated with a linear regression model. This allows a quantitative approximation of future tumor growth and size that will facilitate clinical decision-making.
ANGI-04. BEVACIZUMAB-INDUCED NORMALIZATION OF TUMOR VASCULATURE IN GLIOBLASTOMA
Authors: Norihiko Saito, Kazuya Aoki
Journal: Neuro-Oncology (2016)

Tumor angiogenesis occurs in the setting of a defective vasculature, which is associated with increased vascular permeability and enhanced tumor permeability. Bevacizumab is used to treat malignant glioma and was found to reduce microvascular density and prune abnormal tumor microvessels. We used electron microscopic observation of two autopsy cases to investigate the effects of blood vessel normalization in glioblastoma treated with bevacizumab. Both patients had received bevacizumab by means of the Stupp regimen for glioblastoma recurrence. Using CD31 and SMA immunostaining, we compared initial surgical specimens with postmortem specimens obtained after bevacizumab treatment. The glomerular structure was remarkably reduced in postmortem samples. There was no significant change in the number of tumor vessels. In postmortem samples, marked proliferation of CD31(-)/SMA(+) cells (pericytes) was seen around vessels. Electron microscopic images confirmed the presence of pericytes surrounding the vascular endothelium. These findings indicate that bevacizumab treatment promotes vascular normalization by recruiting mature pericytes. In tumor angiogenesis, vascular endothelial growth factor induces sprouting angiogenesis and recruitment of vascular endothelial cells such as tip cells, stalk cells, and phalanx cells. Fully mature phalanx cells are in close contact with pericytes. These mechanisms might be important in the normalization of tumor vasculature after bevacizumab treatment. Inhibition of multiple angiogenic factors is required in order to control tumor vessels in glioblastoma.
Molecular Remission after Combined Immunochemotherapy Is of Prognostic Relevance in Patients with MCL: Results of the Randomized Intergroup Trials of the European MCL Network
Authors: Christiane Pott, Eva Hoster, Sebastian Böttcher, Reiner Siebert, Wolfram Klapper, Marie Helene Delfau, Michael Unterhalt, Wolfgang Hiddemann, Michael Kneba, Martin Dreyling
Journal: Blood (2008)
Acquired Fms-Like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3 ITD) During Leukaemic Transformation From Underlying Myelodysplasia: Successful Rescue with Sorafenib
Authors: Harinder Gill, Cheuk Him Man, Karen Lam, Raymond Liang, Edmond Ma, Yok Lam Kwong, Anskar Y. H. Leung
Journal: Blood (2012)
A prospective study of low fasting glucose with cardiovascular disease events and all-cause mortality: The Women's Health Initiative
Authors: Morgana Mongraw-Chaffin, Andrea Z. LaCroix, Dorothy D. Sears, Lorena Garcia, Lawrence S. Phillips, Elena Salmoirago-Blotcher, Oleg Zaslavsky, Cheryl A.M. Anderson
Journal: Metabolism (2017)
Expression and Functional Analysis of Activation-Induced Deaminase (AID) in Normal Human B Lymphocytes.
Authors: Xiaosheng Wu, Blair L. Brown, Jaime R. Darce, Bonnie K. Arendt, Sook-Kyung Chang, Renee C. Tschumper, Neil E. Kay, Diane F. Jelinek
Journal: Blood (2006)
Patient-centred approach in a multicenter national study (E-Lung): 405 lung cancer patients and caregivers, nurses and oncologists compared
Authors: R. Torta, V. Ieraci, M. Miniotti, P. Leombruni, M. Airoldi, M. Tiseo, E. Cortesi, F. de Braud, M. Garassino, G. Fasola, C. Iacono, A. Morabito, S. Cascinu, R. Berardi
Journal: Annals of Oncology (2016)
A dose-escalation study of weekly intravenous CRLX301 in patients with advanced solid tumor malignancies
Authors: H. Wang, B. Markman, P. de Souza, E.C. Dees, T.C. Gangadhar, S.A. Piha-Paul, W.C. Zamboni, C. Murphy, A. Senderowicz
Journal: Annals of Oncology (2016)

Cerulean's nanoparticle-drug conjugates (NDCs) are designed to enhance delivery of drugs to tumors while sparing healthy tissues and to gradually release drug payloads once inside tumors with the goal of improving antitumor activity and reducing systemic toxicity. CRLX301 is a novel investigational NDC containing the payload docetaxel covalently conjugated to a cyclodextrin-polyethylene glycol copolymer currently being investigated in a phase 1/2a study of patients with advanced solid tumors. The first portion of the study determined the maximum tolerated dose (MTD) for intravenous (IV) CRLX301 every 3 weeks (Q3W) to be 75 mg/m2 and showed that CRLX301 was generally well tolerated with hints of antitumor activity and a differentiated pharmacokinetic (PK) compared to docetaxel (Wang H, ASCO 2016, Abs. 2526). This portion aims to determine the MTD for weekly administration (QW) of CRLX301. Trial design: We will enroll adults with advanced solid tumors, adequate organ function and ECOG Performance Status 0–1. Simulation modeling with the Q3W PK data suggest that total and released docetaxel will not accumulate in plasma after 9 weeks of QW CRLX301 at 20, 25, 30 or 40 mg/m2. Also, at these doses the estimated total and released docetaxel area under the plasma drug concentration-time curves (AUCs) after the 1st, 4th and 7th doses would not exceed those observed with CRLX301 at 75 mg/m2 Q3W. These results support a weekly starting dose between 20 and 40 mg/m2, so 25 mg/m2 QW (1/3 of the Q3W MTD) was selected. Escalating doses will be tested in a 3 + 3 design. The primary objective is to determine the CRLX301 QW MTD. Secondary objectives include assessments of safety, PK and antitumor activity. Serial plasma samples for PK evaluation will be collected during weeks 1, 4 and 7. Tumors will be evaluated every 8 to 9 weeks per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. A recommended phase 2 dose will be determined for use in the phase 2a expansion in patients with specific tumor types, including taxane-naïve bladder cancer. Data from QW and Q3W studies will be evaluated to select the optimal dosing schedule for future clinical trials of CRLX301. Clinical trial identification: NCT02380677 (NIH) Legal entity responsible for the study: Cerulean Pharma, Inc. Cerulean Pharma, Inc.
Cassidy Rolls Up His Sleeves
Authors: Jeff Lyon
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Heterozygous RTEL1 variants in Patients with Bone Marrow Failure Associate with Telomere Dysfunction in the Absence of Telomere Shortening
Authors: Fernanda Gutierrez-Rodrigues, Sachiko Kajigaya, Xingmin Feng, Maria del Pilar Fernandez Ibanez, Marie J. Desierto, Keyvan Keyvanfar, Zejuan Li, Soma Das, Rodrigo T. Calado, Danielle M. Townsley, Neal S. Young
Journal: Blood (2016)
The value of a tailored evaluation before cancer therapy: is there a way to predict the aftermath of radiotherapy in breast cancer patients? Preliminary data of an observational study
Authors: G. Gallucci, A.M.L. Capobianco, A. Venetucci, M. Aieta, L. Lapadula, R. Gallicchio, G. Storto
Journal: Annals of Oncology (2016)
BMET-20. BRAIN SURFACE CYTOLOGICAL TEST DURING RESECTION OF BRAIN METASTASES AND POSTOPERATIVE LEPTOMENINGEAL CARCINOMATOSIS
Authors: Yoko Nakasu, Koichi Mitsuya, Nakamasa Hayashi, Reiko Watanabe, Ichiro Ito
Journal: Neuro-Oncology (2016)

Brain metastases (BMs) are the most frequent cerebral tumours. Surgery of BMs plays an indispensible role in a multimodal therapy concept. Leptomeningeal carcinomatosis (LC) reportedly occurs 5.4-33% of patients after surgery. Surgical spread of cancer cells has been thought as one of the cause for the development of LC after surgery. We prospectively examined the frequency of spillage of cancer cells during resection surgery, and studied the incidence of LC. A total of 120 patients underwent resection of BM with cytological examination. The brain surface was thoroughly covered with cotton surgical patties, which were washed in saline for cytological examination immediately after surgery. We named this method as cotton dam. Cytological results were positive in 79 (65.8%), highly suspected in one, doubtful in 23, negative in 17 cases. One of two surgical methods was selected according to the eloquency of lesion site: minimum circumferential resection (MCR) in 87 patients, and resection with free margin (RFM) in 33. Seven (5.8%) patients developed LC at a median of three months (range 1.5-12 months) after resection. Six of seven patients had positive cytological result, and only one patient with small-cell lung cancer had doubtful result. Six of seven patients underwent MCR, and one did RFM. There were no increased risks of LC either after posterior fossa surgery or MCR in this series. Spillage of cancer cells occurred more frequently than surgeons had expected. In spite of the high rate of positive cytological result (65.8%), LC occurred in only 5.8% patients. Cotton dam might be useful to block spread of cancer cells on the surgical field of BMs and to select adjuvant therapy. Postsurgical radiation or chemotherapy might contribute to reduce the rate of LC occurrence. Primary cancers may have a variety of tendency to cause LC after surgery for BMs.
NIMG-36. AMINO ACID METABOLISM MEASURED BY PET IS ASSOCIATED WITH SPECIFIC MOLECULAR BIOMARKERS IN PRIMARY GLIOBLASTOMA
Authors: Edit Bosnyak, Sharon K Michelhaugh, Neil V Klinger, Geoffrey R Barger, Sandeep Mittal, Csaba Juhasz
Journal: Neuro-Oncology (2016)

Several molecular markers were shown to provide prognostic information in glioblastomas. Among these, high Ki-67 nuclear labeling index (characterizing tumoral proliferative activity) and overexpression of epidermal growth factor receptor (EGFR) carry an unfavorable prognosis, while O-6-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation and isocitrate dehydrogenase 1 (IDH1) mutation are associated with longer survival. Some of these molecular markers may be associated with specific imaging characteristics including abnormal tumoral amino acid metabolism measured by positron emission tomography (PET). We have previously demonstrated increased transport and metabolic rates of tryptophan in malignant gliomas by alpha[11C]-L-methyl-tryptophan (AMT) PET. In the present study, we evaluated if prognostic molecular markers are associated with tryptophan transport and metabolic rates measured by AMT-PET in newly-diagnosed glioblastomas. Twenty-two patients (15 males, mean age: 62 years) with a suspected glioblastoma underwent presurgical imaging including dynamic AMT-PET following tumor resection and standard postsurgical chemoradiation. Tumoral tryptophan uptake on PET was measured by standardized uptake values (SUV), and kinetic PET parameters were also calculated to estimate tumoral tryptophan transport and metabolism and their tumor/cortex ratios. These PET parameters were correlated with molecular tumor markers. In all 22 patients, histopathology confirmed WHO grade IV glioma with wild type IDH consistent with primary glioblastoma. Mean Ki-67 labeling index was 30% (range: 10-70%). Tumors with MGMT promoter hypermethylation showed lower tumor/cortex AMT metabolic ratios than those with unmethylated MGMT (mean: 1.4 ± 0.5 vs. 2.0 ± 0.6, p=0.03), while high EGFR copy number was associated with elevated Ki-67 labeling index (45 ± 14% vs. 22 ± 6% in low-EGFR tumors, p<0.001), high tumoral tryptophan transport rates (tumor/cortex ratio: 3.6 ± 1.2 vs. 2.4 ± 1.1, p=0.05), and high SUVs (5.8 ± 1.9 vs. 4.6 ± 1.1, p=0.07). Tryptophan transport and metabolic rates, measured by PET, are associated with specific prognostic molecular markers (EGFR gene amplification and MGMT promoter methylation, respectively) in IDH wild-type glioblastoma.
Retrospective Comparison of Azacitidine and Decitabine in the Treatment of Myleodysplastic Syndrome,
Authors: Je-Hwan Lee, Sung-Doo Kim, Yunsuk Choi, Young-Hun Park, Jae Seok Lee, Dae-Young Kim, Jung-Hee Lee, Kyoo-Hyung Lee, Sang Min Lee, Won Sik Lee, Jung Lim Lee, Young-Don Joo
Journal: Blood (2011)
Structural and Complex Chromosomal Aberrations Frequently Develop in Skin Fibroblasts after Allogeneic Stem Cell Transplantation.
Authors: Gero Massenkeil, Petra Zschieschang, Julia Pross, Ingo Tamm, Stephan Neuburger, Christoph Lutz, Oliver Rosen, Bernd Dörken, Renate Arnold
Journal: Blood (2005)
Combination Therapy with Histone Deacetylase Inhibitor Vorinostat Plus Aurora Kinase Inhibitor MK-0457 Leads to Enhanced Lymphoma Cell Killing with Stabilization of p53 and Repression of C-Myc, hTERT, and Myc-Responsive miRNAs
Authors: Leo Kretzner, Anna Scuto, Richard Jove, Stephen J. Forman, Yun Yen, Mark Kirschbaum
Journal: Blood (2008)
Fludarabine Monophosphate as First Line Therapy for Chronic Lymphocytic Leukemia (CLL) - 11 Years Clinical Experience.
Authors: J.E. Novoa, A.L. Rojo, B. Beñaran, R. Draper, H. Calvo, N. Iriondo, L. Diaz, M. Rivero, A. Cabrera, M. Pebet, S. Brignoni, A. Luongo, R. De Bellis
Journal: Blood (2006)
Prolactin as a potential negative predictive factor in metastatic non-small cell lung cancers (NSCLC) patients in treatment with Nivolumab (NIVO)
Authors: S. Caponnetto, M. Mancini, C. Manai, V. Magri, G.M. Iannantuono, D. Pellegrino, C. Mosillo, G. Piesco, G. Pomati, S. Scagnoli, F. Urbano, S. Verkhovskaya, G. Barchiesi, S. Zancla, E. Cortesi
Journal: Annals of Oncology (2016)
The Efficacy of Eribulin Monotherapy after Anthracycline and Taxane in HER2-Negative Metastatic Breast Cancer
Authors: Natsuko Tsushita, Tatsunori Shimoi, Atsuko Kitano, Akihiko Shimomura, Makoto Kodaira, Mayu Yunokawa, Kan Yonemori, Chikako Shimizu, Yasuhiro Fujiwara, Kenji Tamura
Journal: Annals of Oncology (2016)
Evaluation of Charlson comorbidity index as predictor of survival in stage II-III colorectal cancer patients treated with surgery and neoadjuvant/adjuvant chemotherapy: A single Institution observational study
Authors: M. Baretti, N. Personeni, L. Giordano, M.C. Tronconi, T. Pressiani, S. Bozzarelli, L. Rimassa, A. Santoro
Journal: Annals of Oncology (2016)
Trabectedin in combination with pegylated liposomal doxorubicin for patients with ovarian cancer
Authors: K. Tavella, A. Villanucci, L. Vannini, S. Montelatici, D. Lavacchi, L. Boni, D. Tomcikova, G. Amunni, T. Mazzei
Journal: Annals of Oncology (2016)
Outcome disparities by age and 21-gene recurrence score® (RS) result in hormone receptor positive (HR+) breast cancer (BC)
Authors: S. Shak, D.P. Miller, N. Howlader, N. Gliner, W. Howe, N. Schussler, K. Cronin, F.L. Baehner, L. Penberthy, V.I. Petkov
Journal: Annals of Oncology (2016)
Efficacy and safety of nintedanib (NIN)/docetaxel (DOC) in patients with lung adenocarcinoma: Further analyses from the LUME-Lung 1 study
Authors: D. Heigener, M. Gottfried, J. Bennouna, I. Bondarenko, J.-Y. Douillard, M. Krzakowski, A. Mellemgaard, S. Novello, S. Orlov, Y.J. Summers, J. von Pawel, J. Hocke, R. Kaiser, M. Reck
Journal: Annals of Oncology (2016)
Investigating the feasibility of precision medicine in gastrointestinal cancers
Authors: S.Y. Moorcraft, D. Gonzalez De Castro, D. Cunningham, B. Walker, T. Jones, C. Peckitt, S. Hulkki Wilson, A. Wotherspoon, L. Sixeira Te Mendes, R. Begum, Z. Eltahir, L. Yuan, A. Gillbanks, C. Baratelli, N. Valeri, M. Gerlinger, C. Braconi, I. Chau, D. Watkins, N. Starling
Journal: Annals of Oncology (2016)
Bevacizumab combined with 1st line chemotherapy in elderly patients (≥75 years-old) with metastatic colorectal cancer - Interim results according to the chemotherapy regimen (CASSIOPEE)
Authors: L. Mineur, E. Francois, S. Kim, F. Burki, P. Laplaige, S. Gourgou, F. Rollot-Trad, J. Telliez, S. Gandon, D. Smith
Journal: Annals of Oncology (2016)
Early and Permanent Telomere Shortening in Bone Marrow-Derived Cells Following Chemotherapy: A Parallel Study In Vivo in Lymphoma Patients and In Vitro in Cultured Mesenchymal Stem Cells
Authors: Angela Gueli, Marco Ruella, Alessandra Risso, Tiziana Spatola, Hui Jing Hu, Daniela Gottardi, Alberto De Crescenzo, Stefano Buttiglieri, Corrado Tarella
Journal: Blood (2011)
The Incidence of Deep Vein Thrombosis Is Lower in Japanese Patients with Multiple Myeloma Treated with Thalidomide and Corticosteroids or Chemotherapy
Authors: Naoko Takei, Masahiro Kami, Masaharu Tsubokura, Yuji Miura, Takehiro Issiki, Yuji Satou, Kosei Matsue, Tsunehiko Komatsu
Journal: Blood (2008)
Effects of Cystine and Calorie Restriction on the Incidence of Spontaneous Pulmonary Tumors in Strain a Mice
Authors: C. Donald Larsen, Walter E. Heston
Journal: JNCI Journal of the National Cancer Institute (1945)

Journal Article Effects of Cystine and Calorie Restriction on the Incidence of Spontaneous Pulmonary Tumors in Strain a Mice Get access C. Donald Larsen, C. Donald Larsen Search for other works by this author on: Oxford Academic PubMed Google Scholar Walter E. Heston Walter E. Heston Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 6, Issue 1, August 1945, Pages 31–40, https://doi.org/10.1093/jnci/6.1.31 Published: 01 August 1945